John M. Hoffmann

Array ( [id] => 4468914 [patent_doc_number] => 07943344 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-05-17 [patent_title] => 'Hepatocyte growth factor (HGF) binding proteins' [patent_app_type] => utility [patent_app_number] => 12/632765 [patent_app_country] => US [patent_app_date] => 2009-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 34257 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/943/07943344.pdf [firstpage_image] =>[orig_patent_app_number] => 12632765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7662289 [patent_doc_number] => 20110311558 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-22 [patent_title] => 'Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases' [patent_app_type] => utility [patent_app_number] => 13/131514 [patent_app_country] => US [patent_app_date] => 2009-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 18597 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0311/20110311558.pdf [firstpage_image] =>[orig_patent_app_number] => 13131514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7560862 [patent_doc_number] => 20110274694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-10 [patent_title] => 'ERK1/2 Posphorylation Site Specific Antibody' [patent_app_type] => utility [patent_app_number] => 13/130495 [patent_app_country] => US [patent_app_date] => 2009-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 13645 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0274/20110274694.pdf [firstpage_image] =>[orig_patent_app_number] => 13130495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6228860 [patent_doc_number] => 20100183598 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-22 [patent_title] => 'METHODS OF TREATING CARDIOVASCULAR DISORDERS' [patent_app_type] => utility [patent_app_number] => 12/617643 [patent_app_country] => US [patent_app_date] => 2009-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32840 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0183/20100183598.pdf [firstpage_image] =>[orig_patent_app_number] => 12617643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5935924 [patent_doc_number] => 20110212083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-01 [patent_title] => 'ROLE OF SOLUBLE UPAR IN THE PATHOGENESIS OF PROTEINURIC KIDNEY DISEASE' [patent_app_type] => utility [patent_app_number] => 13/127848 [patent_app_country] => US [patent_app_date] => 2009-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 16094 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0212/20110212083.pdf [firstpage_image] =>[orig_patent_app_number] => 13127848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8554717 [patent_doc_number] => 08329186 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-12-11 [patent_title] => 'Treatment of inflammation using BST2 inhibitor' [patent_app_type] => utility [patent_app_number] => 12/611090 [patent_app_country] => US [patent_app_date] => 2009-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 50336 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12611090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7728573 [patent_doc_number] => 08101184 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-01-24 [patent_title] => 'Treatment methods using Dkk-1 antibodies' [patent_app_type] => utility [patent_app_number] => 12/603303 [patent_app_country] => US [patent_app_date] => 2009-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 38907 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/101/08101184.pdf [firstpage_image] =>[orig_patent_app_number] => 12603303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6308195 [patent_doc_number] => 20100069615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-03-18 [patent_title] => 'Regulation of Human Transmembrane Serine Protease' [patent_app_type] => utility [patent_app_number] => 12/579851 [patent_app_country] => US [patent_app_date] => 2009-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 29174 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0069/20100069615.pdf [firstpage_image] =>[orig_patent_app_number] => 12579851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8772598 [patent_doc_number] => 08426555 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-04-23 [patent_title] => 'Acute leukemia and lymphoblastic lymphona-specific CD43 epitope' [patent_app_type] => utility [patent_app_number] => 12/577115 [patent_app_country] => US [patent_app_date] => 2009-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 8176 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12577115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6549966 [patent_doc_number] => 20100233154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-09-16 [patent_title] => 'TARGETED BINDING AGENTS DIRECTED TO HEPARANASE AND USES THEREOF 463' [patent_app_type] => utility [patent_app_number] => 12/575267 [patent_app_country] => US [patent_app_date] => 2009-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 61609 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0233/20100233154.pdf [firstpage_image] =>[orig_patent_app_number] => 12575267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6420167 [patent_doc_number] => 20100150917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-17 [patent_title] => 'Method of Depleting Regulatory T Cell' [patent_app_type] => utility [patent_app_number] => 12/573689 [patent_app_country] => US [patent_app_date] => 2009-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 17884 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0150/20100150917.pdf [firstpage_image] =>[orig_patent_app_number] => 12573689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6433714 [patent_doc_number] => 20100278815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-04 [patent_title] => 'Humanized Monoclonal Antibodies to Hepatocyte Growth Factor' [patent_app_type] => utility [patent_app_number] => 12/569463 [patent_app_country] => US [patent_app_date] => 2009-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 9438 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0278/20100278815.pdf [firstpage_image] =>[orig_patent_app_number] => 12569463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6600781 [patent_doc_number] => 20100098686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-04-22 [patent_title] => 'Method for reducing levels of C-reactive protein' [patent_app_type] => utility [patent_app_number] => 12/585902 [patent_app_country] => US [patent_app_date] => 2009-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8559 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0098/20100098686.pdf [firstpage_image] =>[orig_patent_app_number] => 12585902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6493518 [patent_doc_number] => 20100209427 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-08-19 [patent_title] => 'LYSINE ACETYLATION SITES' [patent_app_type] => utility [patent_app_number] => 12/566523 [patent_app_country] => US [patent_app_date] => 2009-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 76 [patent_figures_cnt] => 76 [patent_no_of_words] => 39510 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0209/20100209427.pdf [firstpage_image] =>[orig_patent_app_number] => 12566523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4476152 [patent_doc_number] => 07868152 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-01-11 [patent_title] => 'Polynucleotides encoding anti-sulfotyrosine antibodies' [patent_app_type] => utility [patent_app_number] => 12/560294 [patent_app_country] => US [patent_app_date] => 2009-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 18144 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/868/07868152.pdf [firstpage_image] =>[orig_patent_app_number] => 12560294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7522727 [patent_doc_number] => 08025882 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-09-27 [patent_title] => 'Interferon alpha antibodies and their uses' [patent_app_type] => utility [patent_app_number] => 12/551250 [patent_app_country] => US [patent_app_date] => 2009-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 30412 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/025/08025882.pdf [firstpage_image] =>[orig_patent_app_number] => 12551250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7560864 [patent_doc_number] => 20110274696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-10 [patent_title] => 'ANTIBODIES TO CCR2' [patent_app_type] => utility [patent_app_number] => 13/059702 [patent_app_country] => US [patent_app_date] => 2009-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 37475 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0274/20110274696.pdf [firstpage_image] =>[orig_patent_app_number] => 13059702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5551841 [patent_doc_number] => 20090285827 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-11-19 [patent_title] => 'ANTAGONIST ANTIBODIES AGAINST GDF-8 AND USES IN TREATMENT OF ALS AND OTHER GDF-8 ASSOCIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 12/508618 [patent_app_country] => US [patent_app_date] => 2009-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 32916 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0285/20090285827.pdf [firstpage_image] =>[orig_patent_app_number] => 12508618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5551816 [patent_doc_number] => 20090285802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-11-19 [patent_title] => 'HIGHLY CONCENTRATED STABILIZED IGM SOLUTION' [patent_app_type] => utility [patent_app_number] => 12/509075 [patent_app_country] => US [patent_app_date] => 2009-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 10604 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0285/20090285802.pdf [firstpage_image] =>[orig_patent_app_number] => 12509075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8184136 [patent_doc_number] => 20120114660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-10 [patent_title] => 'Antibodies Against LLG Polypeptides of the Triacylglycerol Lipase Family' [patent_app_type] => utility [patent_app_number] => 12/503778 [patent_app_country] => US [patent_app_date] => 2009-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 18943 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0114/20120114660.pdf [firstpage_image] =>[orig_patent_app_number] => 12503778 [rel_patent_id] =>[rel_patent_doc_number] =>)